Urinary mRNA expression of CCN2/CCN3 as a noninvasive marker for monitoring glomerular structure changes in nondiabetic chronic kidney disease

Biomarkers

Volumn 17, Issue 8, 2012, Pages 714-720

  Chen, Long ^a   Wu, Yong Gui ^b   Liu, Dan ^a   Lv, Lin Li ^a   Zheng, Min ^a   Ni, Hai Feng ^a   Cao, Yu Han ^a   Liu, Hong ^a   Zhang, Pei ^b   Zhang, Jian Dong ^a   Liu, Bi Cheng ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; CCN2; CCN3; Nondiabetic CKD; Urinary mRNA

Indexed keywords

BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; NEPHROBLASTOMA OVEREXPRESSED PROTEIN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; GLOMERULAR STRUCTURE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MALE; PATIENT MONITORING; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; URINE LEVEL;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; GENE EXPRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84870541832     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.722229     Document Type: Article

References (29)

1. Bramham K, Mistry HD, Poston L, Chappell LC, Thompson AJ. (2009). The non-invasive biopsy-will urinary proteomics make the renal tissue biopsy redundant? QJM 102:523-538.
2. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C. (2006). ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70:781-787.
3. Cicha I, Goppelt-Struebe M. (2009). Connective tissue growth factor: context-dependent functions and mechanisms of regulation. Biofactors 35:200-208.
4. Colburn WA. (2003). Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 43:329-341.
5. Colucci G, Floege J, Schena FP. (2006). The urinary sediment beyond light microscopical examination. Nephrol Dial Transplant 21:1482-1485.
6. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. (2007). Prevalence of chronic kidney disease in the United States. JAMA 298:2038-2047.
7. de Jong PE, Gansevoort RT. (2010). Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant 25:656-658.
8. Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R. (2011). Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 16:289-301.
9. El Nahas AM, Bello AK. (2005). Chronic kidney disease: the global challenge. Lancet 365:331-340.
10. Goumenos DS, Tsakas S, El Nahas AM, Alexandri S, Oldroyd S, Kalliakmani P, Vlachojannis JG. (2002). Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 17:2145-2152.
11. Gupta S, Clarkson MR, Duggan J, Brady HR. (2000). Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58:1389-1399.
12. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. (2008). A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 19:329-338.
13. Leask A. (2012). CCN3: a novel anti-fibrotic treatment in end-stage renal disease? J Cell Commun Signal 6:115-116.
14. Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B, Serur D, Mouradian J, Schwartz JE, Suthanthiran M. (2001). Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 344:947-954.
15. Liu BC, Huang HQ, Luo DD, Ma KL, Liu DG, Liu H. (2006). Connective tissue growth factor is associated with the early renal hypertrophy in uninephrectomized diabetic rats. Chin Med J 119:1010-1016.
16. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. (2006). Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937-2944.
17. Macisaac RJ, Jerums G. (2011). Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 20:246-257.
18. Riser BL, Cortes P, DeNichilo M, Deshmukh PV, Chahal PS, Mohammed AK, Yee J, Kahkonen D. (2003). Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 64:451-458.
19. Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC. (2009). CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174:1725-1734.
20. Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, Chang JW, Wiggins JE, Lienczewski C, Kretzler M, Wiggins RC. (2009). Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 20:1041-1052.
21. Scheckner B, Peyser A, Rube J, Tarapore F, Frank R, Vento S, Hoffman C, Valderrama E, Charney D, Goilav B, Trachtman H. (2009). Diagnostic yield of renal biopsies: a retrospective single center review. BMC Nephrol 10:11.
22. Szeto CC, Chan RW, Lai KB, Szeto CY, Chow KM, Li PK, Lai FM. (2005a). Messenger RNA expression of target genes in the urinary sediment of patients with chronic kidney diseases. Nephrol Dial Transplant 20:105-113.
23. Szeto CC, Lai KB, Chow KM, Szeto CY, Yip TW, Woo KS, Li PK, Lai FM. (2005b). Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin Chim Acta 361:182-190.
24. Szeto CC, Chow KM, Lai KB, Szeto CY, Chan RW, Kwan BC, Chung KY, Li PK, Lai FM. (2006). mRNA expression of target genes in the urinary sediment as a noninvasive prognostic indicator of CKD. Am J Kidney Dis 47:578-586.
25. Urbschat A, Obermüller N, Haferkamp A. (2011). Biomarkers of kidney injury. Biomarkers 16 Suppl 1:S22-S30.
26. van Roeyen CR, Eitner F, Scholl T, Boor P, Kunter U, Planque N, Gröne HJ, Bleau AM, Perbal B, Ostendorf T, Floege J. (2008). CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 73:86-94.
27. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. (2012). Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379:815-822.
28. Zheng M, Lv LL, Ni J, Ni HF, Li Q, Ma KL, Liu BC. (2011). Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS ONE 6:e20431.
29. Zheng M, Lv LL, Cao YH, Zhang JD, Wu M, Ma KL, Phillips AO, Liu BC. (2012). Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy. Clin Endocrinol (Oxf) 76:657-664.